Clinical Trials Logo

Liver Cirrhosis clinical trials

View clinical trials related to Liver Cirrhosis.

Filter by:

NCT ID: NCT04576572 Completed - Clinical trials for Hepatocellular Carcinoma

Comparison of Criteria for Liver Transplantation in Hepatocellular Carcinoma

Start date: June 15, 2020
Phase:
Study type: Observational

Hepatocellular cancer is the 6th most common seen disease in the world and the 3rd in cancer-related deaths. Liver transplantation is the primary curative treatment of HCC, as it eliminates liver cancer and underlying cirrhosis. However, liver transplantation is not offered to every HCC patient, since advanced stage HCC patients are lost with tumor recurrence early after liver transplantation. The Milan criteria, which are accepted worldwide, are the patient selection criteria that we have to follow in cadaver-to-liver transplantation for HCC in our country. However, as the Milan criteria are very strict criteria, it pushes patients out of liver transplantation who exceed the Milan criteria but who can benefit from liver transplantation. Liver transplantation centers all over the world have declared their own criteria under the expanded Milan criteria. In our country, Malatya Criteria have been defined by İnönü University on this subject, and our studies on this subject still continue. When we scan the original articles of all these defined criteria, incomplete data are formed and therefore the strength of the criteria cannot be clearly revealed. For this reason, we aimed to analyze the results of our center and present information about the power of the criteria to the literature.

NCT ID: NCT04573543 Completed - Clinical trials for Non-Alcoholic Fatty Liver Disease

The Role of Immune Semaphorins in NAFLD

SepsisFAT
Start date: September 1, 2020
Phase:
Study type: Observational

To goal is to identify semaphorins that are associated with NAFLD and to investigate their relationship with variable degrees of steatosis and fibrosis.

NCT ID: NCT04561804 Completed - Weight Loss Clinical Trials

NAFLD and Liver Fibrosis in Obese Adolescents

NAFLD
Start date: December 1, 2018
Phase:
Study type: Observational [Patient Registry]

Nonalcoholic fatty liver disease (NAFLD) is a chronic liver disease resulting from excessive fat accumulation in the liver. Due to its close association with obesity, it has become the most common liver disease in children in the United States. NAFLD can result in progressive fibrosis and lead to end-stage liver disease. Best practices in management of pediatric NAFLD are not clearly defined. Our aim is to clarify the natural history of NAFLD in obese children after weight loss surgery compare to lifestyle intervention. Our secondary aim is to investigate the added value of elastography for the screening and diagnosis of NASH with fibrosis.

NCT ID: NCT04559126 Completed - Clinical trials for NASH - Nonalcoholic Steatohepatitis With Liver Fibrosis

A Study of EDP-297 in Healthy Subjects

Start date: September 8, 2020
Phase: Phase 1
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-297 in healthy adult subjects.

NCT ID: NCT04557774 Completed - Clinical trials for Alcoholic Liver Disease

Cognitive Function of Alcoholic Compensated Liver Cirrhosis

Start date: October 1, 2011
Phase:
Study type: Observational

Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis

NCT ID: NCT04553328 Completed - Liver Cirrhosis Clinical Trials

Ultrasound-guided Ipsilateral Transverse Abdominis Plane and Ilioinguinal Iliohypogastric Nerve Block.

Start date: September 1, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the efficacy of using TAB and ILIH nerve blocks versus ILIH nerve block only for inguinal hernia repair in patients with liver cirrhosis.

NCT ID: NCT04543643 Not yet recruiting - Clinical trials for Gastroesophageal Varices

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

CABER
Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal. Berberine can regulate the intestinal flora.In this study, we evaluated the effect of carvedilol and berberine on reducing portal vein pressure by observing the changes of endoscopy,endoscopic ultrasonography and intestinal flora.

NCT ID: NCT04539717 Enrolling by invitation - Liver Cirrhosis Clinical Trials

FAST (Focused Abbreviated Screening Technique)-MRI Study

Start date: August 17, 2020
Phase:
Study type: Observational

The purpose of this study is to compare the diagnostic value of a reconstructed abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to determine their correlation to imaging. This study will help to determine whether abbreviated MRI is superior to ultrasound for diagnosis of liver cancer.

NCT ID: NCT04533932 Recruiting - Liver Cirrhosis Clinical Trials

Endosonographic Shear Wave Elastography for Liver Stiffness

Start date: September 8, 2020
Phase:
Study type: Observational

This is a single-center, prospective, non-randomized, comparative study which will compare the diagnostic accuracy and safety of endosonographic real-time Elastography and shear wave Elastography with the current standards of care, i.e. liver biopsy and Vibration-controlled transient elastography (Fibroscan). Subjects who are referred for an endoscopic ultrasound (EUS) guided liver biopsy will be prospectively enrolled to undergo liver biopsy, Elastography and/or Vibration-controlled transient elastography.

NCT ID: NCT04533828 Recruiting - Liver Fibrosis Clinical Trials

68Ga-FAPI PET/CT in Liver Fibrosis Patients

GFAPILF
Start date: September 1, 2020
Phase: Early Phase 1
Study type: Interventional

To evaluate the potential value of 68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT) for the diagnosis and prognosis in liver fibrosis disease.